Jump to content

Search the Community

Showing results for tags 'clinical trials'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 11 results

  1. Some members may not be aware of PlayLists on YouTube. The TheraP Lutetium-177 trial reminds me that there is a great video on clinical trials starring our own Tony Maxwell on our Advanced Prostate Cancer Stories playlist. You can go to the playlist directly by clicking: https://www.youtube.com/playlist?list=PLvCNVWCC5ca9lyb0I9G3ktq7cDsZf_WSy Or you can see all our playlists on our YouTube channel: https://youtube.com/c/JimJimJimJim PS: Although I do almost all the videos on our channel, there are a couple of ring-ins done by professionals. The one with Tony Maxwell is one of these.
  2. "A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value." Click here to read what the New Prostate Cancer Infolink says about this article.
  3. "Another new form of radioisotope, copper-64 (64Cu), has recently undergone Phase I clinical testing for similar uses when linked to the PSMA-617 ligand. One of the potential benefits of a 64Cu-PSMA imaging agent is that it is more stable and has a longer half-life than 68Ga. This means that this imaging agent could be made at a central facility and distributed from there to clinical PET scan centers that don’t have the radiochemistry capabilities necessary for the preparation of 68Ga-PSMA imaging agents." The New Prostate Cancer Infolink has a report on the trial carried out at two nuclear medicine centers (in Vienna, Austria, and Bad Berka, Germany).
  4. Thanks to Rick Davis and our American friends at Answer Cancer Foundation for telling us about this webinar.
  5. When clinical trials fail, this information is most often not reported. The Obama administration will be publishing new rules pertaining to the public disclosure of clinical trial results. These rules will allow both doctors and patients learn if clinical trials of treatments worked or not. Click here to read Malecare's report about the requirement to disclose the results of clinical trials.
  6. Three times a year the Prostate Cancer Foundation of Australia (PCFA) publishes Prostate News. Click this sentence to see all issues of Prostate News. Some interesting things to see in the current (August 2016) issue: Pathfinder is the national online register of men and women interested in participating in prostate cancer research. Current research projects listed on Pathfinder include: A randomised controlled trial of iCanADAPT, an internet Cognitive Behavioural Therapy program for the treatment of depression and anxiety in early-stage cancer patients and cancer survivors (NSW) The Men and Sexual Health-Prostate Cancer (MaSH-PC) study (Qld) Do Australian men with prostate cancer have access to well-designed websites with quality content information to encourage physical exercise?(SA)Rekindle: testing an online resource to promote sexual wellbeing for both patients and their partners (NSW) Click this sentence to go to Pathfinder to register yourself for clinical trials. Also in this issue, PCFA's scientific writer, Wendy Winnall, reports Dr Melissa Hyde's study of Australian men's unmet needs in prostate cancer, and how they access information (78% doctor's resources, 53% internet, 8% support group, 4.5% cancer helplines, and 2.1% counselling services). PCFA CEO, Anthony Lowe, has an article on what patient expectations are for their treatment. Finally, a great looking pair of Steel Blue boots (non-safety) for $99 (with $10 going to PCFA). Click this sentence to all issues of Prostate News.
  7. Apalutamide (JNJ-56021927 formerly known as ARN 509) is a novel small-molecule androgen receptor antagonist similar to enzalutamide but with less central nervous system penetration, which could potentially result in reduced levels of fatigue and seizures. Curetoday.com has an article about 2 Phase 3 clinical trials of Apalutamide: the ATLAS trial (NCT02531516; learn more here); the SPARTAN study (NCT01946204; learn more here). The SPARTAN study is currently recruiting in Australia; the ATLAS study is not. For SPARTAN, eligible patients must show no signs of evident metastatic prostate cancer and must have a high risk for disease progression. A high risk for disease progression is defined as either a PSA doubling time (PSADT) of less than 10 months while on continuous ADT, or Castrate Resistant Prostate cancer demonstrated while on continuous ADT. PSADT is calculated using at least three PSA values during ADT.
  8. This may be a drug to watch in the future. Seviteronel (VT-464) is a once-daily oral therapeutic given without prednisone. Seviteronel selectively inhibits CYP17 lyase, a target of abiraterone, and has unique blocking effects on the androgen receptor (AR), the target of enzalutamide. There is a growing body of preclinical and clinical evidence that shows that some abiraterone- or enzalutamide-resistant patients will respond to seviteronel treatment. Currently there are phase II clinical trials of seviteronel in the US and Europe. At the moment there are not any clinical trials of this drug in Australia. In January 2016 the United States Food and Drug Administration (FDA) granted Fast Track Designation for seviteronel for the treatment of patients with metastatic castrate-resistant prostate cancer. The Fast Track program is designed to facilitate the development and review of drugs intended to treat serious conditions and fill an unmet medical need.
  9. "It is clear from these data that apalutamide has activity in the treatment of men with nmCRPC. This is not a surprise. However, the degree of promise for apalutamide based on these data (compared to other drugs already available on the market) is much harder to evaluate. Would treatment of this set of patients with either enzalutamide or abiraterone acetate have shown similar outcomes? We really don’t know." Click on this link to read an article in the New Prostate Cancer Infolink about a recent Phase II trial.
  10. The website http://www.australiancancertrials.gov.au is a good place to search for clinical trials that are being conducted in Australia. At the moment there are currently 57 clinical trials for prostate cancer in Australia that are recruiting participants: 28 of these are for men with locally advanced or locally recurrent cancer. 24 of these are for men with metastatic/widespread cancer.
  11. This post in the New Prostate Cancer Infolink suggests that "the failure of this drug to demonstrate significant efficacy in either one of two Phase III trials for the treatment of metastatic, castration-resistant prostate cancer has surely ended any attempt to develop this drug for the treatment of prostate cancer."
×
×
  • Create New...